|
Name |
N-(5-Bromo-2-pyridinyl)-1-naphthamide
|
Molecular Formula | C16H11BrN2O | |
IUPAC Name* |
N-(5-bromopyridin-2-yl)naphthalene-1-carboxamide
|
|
SMILES |
C1=CC=C2C(=C1)C=CC=C2C(=O)NC3=NC=C(C=C3)Br
|
|
InChI |
InChI=1S/C16H11BrN2O/c17-12-8-9-15(18-10-12)19-16(20)14-7-3-5-11-4-1-2-6-13(11)14/h1-10H,(H,18,19,20)
|
|
InChIKey |
UJCUUCDYODTCMG-UHFFFAOYSA-N
|
|
Synonyms |
N-(5-Bromo-2-pyridinyl)-1-naphthamide; N-(5-bromopyridin-2-yl)naphthalene-1-carboxamide; CBDivE_011930; MLS001179613; CHEMBL1869878; ZINC31387; HMS2800D03; STK412607; AKOS003287738; SMR000476615; N-(5-Bromo-2-pyridinyl)-1-naphthamide #; Naphthalene-1-carboxamide, N-(5-bromo2-pyridyl)-; SR-01000200799; SR-01000200799-1
|
|
CAS | NA | |
PubChem CID | 593268 | |
ChEMBL ID | CHEMBL1869878 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 327.17 | ALogp: | 4.0 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 42.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 20 | QED Weighted: | 0.734 |
Caco-2 Permeability: | -4.671 | MDCK Permeability: | 0.00001310 |
Pgp-inhibitor: | 0.027 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.52 | Plasma Protein Binding (PPB): | 96.64% |
Volume Distribution (VD): | 0.393 | Fu: | 3.77% |
CYP1A2-inhibitor: | 0.966 | CYP1A2-substrate: | 0.205 |
CYP2C19-inhibitor: | 0.921 | CYP2C19-substrate: | 0.108 |
CYP2C9-inhibitor: | 0.807 | CYP2C9-substrate: | 0.86 |
CYP2D6-inhibitor: | 0.86 | CYP2D6-substrate: | 0.805 |
CYP3A4-inhibitor: | 0.328 | CYP3A4-substrate: | 0.25 |
Clearance (CL): | 2.01 | Half-life (T1/2): | 0.281 |
hERG Blockers: | 0.343 | Human Hepatotoxicity (H-HT): | 0.819 |
Drug-inuced Liver Injury (DILI): | 0.966 | AMES Toxicity: | 0.358 |
Rat Oral Acute Toxicity: | 0.946 | Maximum Recommended Daily Dose: | 0.587 |
Skin Sensitization: | 0.11 | Carcinogencity: | 0.146 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.784 |
Respiratory Toxicity: | 0.89 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000167 | 0.406 | D01AXB | 0.364 | ||||
ENC001018 | 0.375 | D0O6IZ | 0.359 | ||||
ENC001354 | 0.337 | D00IBN | 0.356 | ||||
ENC000047 | 0.333 | D0B4DC | 0.355 | ||||
ENC001388 | 0.329 | D00HPK | 0.352 | ||||
ENC001511 | 0.327 | D05FTJ | 0.350 | ||||
ENC000675 | 0.324 | D03YGR | 0.347 | ||||
ENC000209 | 0.321 | D0U1OM | 0.345 | ||||
ENC001428 | 0.321 | D02NTO | 0.344 | ||||
ENC000093 | 0.320 | D0H5LK | 0.344 |